Seeking Alpha

Seeking Alpha Portfolio App for iPad

Peter Geschek

Peter Geschek picture

on Healthcare

Profile

Send Message

View as an RSS Feed

View Peter Geschek's Articles BY TICKER:

Bristol Myers Squibb And The New Wave Of Cancer Drugs
on Mon, May 20 • BMY, RHHBY.OB, MRK • Comment!
Johnson & Johnson, Medtronic Frontrunners In Race To Develop Artificial Pancreas
on Thu, May 16 • JNJ, MDT • Comment!
Pfizer's Direct-To-Consumer Campaigns: A Model For The Future?
on Mon, May 13 • PFE • 2 Comments
Billions In Renal Denervation: Medtronic, St. Jude
on Fri, May 10 • MDT, STJ • 1 Comment
After AbbVie's Humira: What Next?
on Mon, May 6 • ABBV, ITMN, AMGN • 1 Comment
EPO Pills: A Challenge For Amgen And Johnson & Johnson
on Thu, May 2 • AMGN • Comment!
Enbrel's Asian Biosimilar Competitors
on Fri, Apr 26 • PFE, AMGN, CPLFY.OB • 1 Comment
Eli Lilly's Big Bet On Diabetes
on Tue, Apr 23 • LLY • 1 Comment
Merck's Promising Vaccine Empire
on Fri, Apr 19 • MRK • 2 Comments
Sarepta Vs Glaxo In The Race To Treat Muscular Dystrophy
on Wed, Apr 17 • SRPT • 11 Comments
Is Celgene's Apremilast A Potential Blockbuster Or Not?
on Thu, Apr 11 • CELG, AMGN, ABBV • 3 Comments
Abbott Laboratories' Golden Goose: The Nutrition Business
on Tue, Apr 9 • ABT • 5 Comments
Pfizer's Prevnar 13: The World's Leading Vaccine And Its Competitors
on Thu, Apr 4 • PFE • Comment!
Johnson & Johnson's New Diabetes Drug And Its Competitors
on Mon, Apr 1 • JNJ • 4 Comments
Celgene's Star Drug Revlimid And Its Competitors
on Sat, Mar 30 • CELG • 1 Comment
Biogen And The Progress In Multiple Sclerosis Treatment
on Mon, Mar 25 • BIIB • 4 Comments
Gilead And Its Competitors In The Hepatitis C Race
on Thu, Mar 21 • GILD • 7 Comments
Express Scripts And The Battle With High Drug Prices
on Mon, Mar 18 • ESRX • 2 Comments
Amgen's Master Plan To Generate Biosimilar Blockbusters
on Fri, Mar 15 • AMGN • 2 Comments
Agilent And The Boom In Companion Diagnostics
on Thu, Mar 14 • PFE, LLY, AMGN • 2 Comments
Alexion And The Super Drugs At Super High Prices
on Mon, Mar 11 • ALXN • Comment!
Pfizer's Xalkori And The Progress In Lung Cancer Drugs
on Wed, Mar 6 • PFE • 1 Comment
Amgen Benefits From Affymax Recall
on Tue, Mar 5 • AMGN, AFFY • 3 Comments
Roche, Genentech And The Cancer Drug Billionaires
on Thu, Feb 28 • RHHBY.OB, NVS • Comment!
Johnson & Johnson's Pioneering Zytiga And Its Competitors
on Sun, Feb 24 • JNJ • 1 Comment
Pfizer's Long-Term Strategy: A Possible Breakup
on Mon, Feb 18 • PFE • 5 Comments
Celgene And The Race To Cure Multiple Myeloma
on Fri, Feb 15 • CELG • 3 Comments
How Safe Is Abbvie's Dividend?
on Tue, Feb 12 • ABBV • 4 Comments
Bright Prospects For The New Abbott
on Fri, Feb 8 • ABT • 7 Comments
Intuitive Surgical Fighting Off Short Sellers
on Fri, Feb 1 • ISRG • 12 Comments
Stryker Increases Dividends, Expands In China
on Wed, Jan 30 • SYK • Comment!
Bristol-Myers Squibb's Dividend Increase And Promising New Drugs
on Tue, Jan 29 • BMY • 2 Comments